Forget Tagrisso's $3B sales target. It'll be worth double that by 2023, analyst says
admin 25th June 2018 Uncategorised 0Tagrisso’s recent approvals in first-line lung cancer have AstraZeneca management optimistic about the $3 billion sales target it set years ago. But some analysts have higher hopes—and one just came up with a far more bullish estimate.
More: Forget Tagrisso's B sales target. It'll be worth double that by 2023, analyst says
Source: fierce